/
Dermatology
Androgenetic Alopecia
11
Pipeline Programs↗
24
Active Trials↗
20
Companies Involved↗
Androgenetic Alopecia is an emerging landscape with 11 programs across 20 companies. The most active players are Chong Kun Dang Pharmaceutical, Olix Pharmaceuticals, Inc., Follicle Pharma Ltd. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 25
Phase 33
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
6 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 73% of 11 pipeline programs.
Analysis
Trial Status
85
clinical trials
Completed40 · 47%
Unknown status16 · 19%
Not yet recruiting10 · 12%
Recruiting10 · 12%
Withdrawn4 · 5%
Active, not recruiting3 · 4%
Other2 · 2%
Clinical Trials
Trial Activity
85 trials
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of XVIE Injected Intradermally in Patients With Androgenetic Alopecia
Not yet recruiting·RRestore Biologics Holdings, Inc. dba Xtressé·Preclinical·NCT07482423·30 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)